Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients.
The pharmacokinetics of thalidomide in nine human immunodeficiency virus-infected patients were studied. Single doses of thalidomide were well absorbed, with mean peak concentrations (+/- standard deviations) of 1.17 +/- 0.21 and 3.47 +/- 1.14 microg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h. Adverse effects were mild, with drowsiness being reported for seven of nine patients.
Piscitelli
S C
SC
Department of Pharmacy, Clinical Center, National Institutes of Health, Bethesda, Maryland 20892, USA. spisc@nih.gov
Figg
W D
WD
Hahn
B
B
Kelly
G
G
Thomas
S
S
Walker
R E
RE
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013792:Thalidomide / Q000493:pharmacokinetics*
D013792:Thalidomide